SLXN Silexion Therapeutics Corp - Ordinary Shares
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q May 19, 2026SLXN Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
SLXN Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
| Ex-date | Split | Type |
|---|---|---|
| May 29, 2026 | 1-for-10 | Reverse |
| July 29, 2025 | 1-for-15 | Reverse |
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | SLXN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | 0.2 | · | · | · | |
| P/B (MRQ) | 2.8 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | SLXN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 1.0 | · | 2.5 | Low liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 14, 2026 | $-5.17 | $-2.16 | -139.1% |
| March 31, 2026 | May 15, 2026 | $-8.50 | $-13.16 | 35.4% |
| Dec. 31, 2025 | $-14.00 | $-11.42 | -22.5% | |
| Sept. 30, 2025 | $-28.80 | $-34.68 | 17.0% | |
| June 30, 2025 | $-43.20 | $-36.72 | -17.6% | |
| March 31, 2025 | $-3.90 | $-3.37 | -15.9% | |
| Dec. 31, 2024 | $-311.40 | $-14.99 | -1976.8% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Balance Sheet
| Metric | Trend | 2025 |
|---|---|---|
| Cash & Equivalents | $6M | |
| Prepaid Expense | $570.0K | |
| Other Current Assets | $49.0K | |
| Current Assets | $7M | |
| PP&E (Net) | $25.0K | |
| Total Assets | $7M | |
| Accrued Liabilities | $859.0K | |
| Current Liabilities | $3M | |
| Capital Leases | $286.0K | |
| Total Liabilities | $5M | |
| Common Stock | $42.0K | |
| Paid-in Capital | $58M | |
| Retained Earnings | $-55M | |
| Stockholders' Equity | $3M | |
| Liabilities + Equity | $7M | |
| Shares Outstanding | 3,126,651 |
Per Share
| Metric | Trend | 2025 |
|---|---|---|
| EPS (TTM) | $8.96 |
Valuation (TTM)
| Metric | Trend | 2025 |
|---|---|---|
| Net Income TTM | $-12M | |
| P/E | 0.2 | |
| Earnings Yield | 466.7% |
Income Statement
| Metric | Trend | Q1 2026 | Q1 2025 |
|---|---|---|---|
| R&D Expense | $1M | $590.0K | |
| SG&A Expense | $1M | $1M | |
| Operating Expenses | $3M | $2M | |
| Operating Income | $-3M | $-2M | |
| Interest Income | $32.0K | $2.0K | |
| Other Non-op | $4.0K | $3.0K | |
| Pretax Income | $-3M | $-2M | |
| Net Income | $-3M | $-2M | |
| EPS (Basic) | $0.85 | $3.84 | |
| EPS (Diluted) | $0.85 | $3.84 | |
| Shares (Basic) | 3,230,378 | 451,990 | |
| Shares (Diluted) | 3,230,378 | 451,990 | |
| EBITDA | $-3M | · |
Balance Sheet
| Metric | Trend | Q1 2026 | Q1 2025 |
|---|---|---|---|
| Cash & Equivalents | $2M | · | |
| Prepaid Expense | $2M | · | |
| Other Current Assets | $96.0K | · | |
| Current Assets | $4M | · | |
| PP&E (Net) | $23.0K | · | |
| Total Assets | $5M | · | |
| Accrued Liabilities | $799.0K | · | |
| Current Liabilities | $4M | · | |
| Capital Leases | $251.0K | · | |
| Total Liabilities | $4M | · | |
| Common Stock | $46.0K | · | |
| Paid-in Capital | $58M | · | |
| Retained Earnings | $-58M | · | |
| Stockholders' Equity | $291.0K | · | |
| Liabilities + Equity | $5M | · | |
| Shares Outstanding | 3,126,651 | · |
Cash Flow
| Metric | Trend | Q1 2026 | Q1 2025 |
|---|---|---|---|
| Stock-based Comp | $345.0K | $21.0K | |
| Operating Cash Flow | $-4M | $-2M | |
| CapEx | $0 | $6.0K | |
| Investing Cash Flow | $0 | $-6.0K | |
| Stock Issued | $83.0K | $0 | |
| Net Stock Activity | $83.0K | · | |
| Financing Cash Flow | $83.0K | $7M | |
| Free Cash Flow | $-4M | · |
Profitability
| Metric | Trend | Q1 2026 | Q1 2025 |
|---|---|---|---|
| ROA | -42.3% | · | |
| ROE | -190.0% | · |
Liquidity & Solvency
| Metric | Trend | Q1 2026 | Q1 2025 |
|---|---|---|---|
| Current Ratio | 1.0 | · | |
| Quick Ratio | 0.6 | · |
Per Share
| Metric | Trend | Q1 2026 | Q1 2025 |
|---|---|---|---|
| Book Value / Share | $0.09 | · | |
| Cash Flow / Share | $-1.13 | · | |
| Cash / Share | $0.77 | · | |
| EPS (TTM) | $48.42 | · |
Valuation (TTM)
| Metric | Trend | Q1 2026 | Q1 2025 |
|---|---|---|---|
| Net Income TTM | $-13M | · | |
| Market Cap | $4M | · | |
| P/E | 0.0 | · | |
| P/B | 13.8 | · | |
| P / Tangible Book | 13.8 | · | |
| P / Cash Flow | -1.1 | · | |
| Earnings Yield | 3782.8% | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Not enough fundamentals data to build this statement yet.
Not enough fundamentals data to build this statement yet.
Not enough fundamentals data to build this statement yet.
Institutional owners (13F)
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 1 (-1 vs prior Q) | 0 (0 vs prior Q) | 1 (0 vs prior Q) | 2 (+2 vs prior Q) | +18K |
Compared to Q4 2025. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
Activists & 5%+ owners 4 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Moringa Sponsor, LP, Moringa Partners Ltd, Ilan Levin ×3 filings | May 29, 2026 | 32.99% | Amendment | · | SEC |
| Wildcat Capital Management, LLC, Wildcat Partner Holdings, LP, Leonard A. Potter | June 26, 2025 | 1.30% | Amendment | · | SEC |
| Guangzhou Sino-Israel Bio-Industry Investment Fund (LLP), Avner Lushi, Shlomo Noy | Nov. 20, 2024 | · | Initial filing | Passive investment | SEC |
| Wildcat Capital Management, LLC (2), Wildcat Partner Holdings, LP, Leonard A. Potter (2) | Aug. 22, 2024 | · | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 8 insiders · 3 officers · 6 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Ilan Hadar | Chairman and CEO | June 4, 2026 A | 16,547 | 0 | 0 | $0 |
| Hadar Mirit Horenshtein | CFO and Secretary | June 4, 2026 A | 12,515 | 0 | 0 | $0 |
| Mitchell Shirvan | CSO and CDO | June 4, 2026 A | 8,789 | 0 | 1 | $-31,032 |
| Amnon Peled | Director | Feb. 20, 2026 A | 8,237 | 0 | 0 | $0 |
| Dror Yosef Abramov | Director | Feb. 20, 2026 A | 10,180 | 0 | 0 | $0 |
| Avner Lushi | Director | Feb. 20, 2026 A | 25,399 | 0 | 0 | $0 |
| Shlomo Noy | Director | Feb. 20, 2026 A | 25,399 | 0 | 0 | $0 |
| Ruth Alon | Director | Feb. 20, 2026 A | 10,228 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
SLXN Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
1 analysts · 2026-10-01Mean target $5.00 +1823.8%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.